var data={"title":"Sodium phenylacetate and sodium benzoate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium phenylacetate and sodium benzoate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6969?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium phenylacetate and sodium benzoate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sodium phenylacetate and sodium benzoate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221922\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ammonul</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221934\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Urea Cycle Disorder (UCD) Treatment Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221923\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Administer as a loading dose over 90 to 120 minutes, followed by an equivalent maintenance infusion given over 24 hours. Initiate therapy as soon as the diagnosis of hyperammonemia is made; hyperammonemic coma in neonates should be aggressively treated while the diagnosis is pursued. Dosage is based on weight for neonates, infants, and young children and body surface area for older children, adolescents, and adults.  Therapy should continue until ammonia levels are in normal range or patient can tolerate oral nutrition and medications. Repeat loading doses are not recommended due to neurotoxicity associated with prolonged plasma levels of phenylacetate. Antiemetics may be administered during infusion to aid control of infusion-associated nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders): </b> IV: 55 mL/m<sup>2</sup> (provides sodium phenylacetate 5.5 g/m<sup>2</sup> and sodium benzoate 5.5 g/m<sup>2</sup>) coadministered with arginine; consider conjunctive use of hemodialysis in patients with severe hyperammonemia or refractory to sodium phenylacetate/sodium benzoate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221929\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sodium phenylacetate and sodium benzoate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Administer as a loading dose over 90 to 120 minutes, followed by an equivalent maintenance infusion given over 24 hours. Initiate therapy as soon as the diagnosis of hyperammonemia is made; hyperammonemic coma in neonates should be aggressively treated while the diagnosis is pursued. Dosage is based on weight for neonates, infants, and young children and body surface area for older children, adolescents, and adults.  Therapy should continue until ammonia levels are in normal range or patient can tolerate oral nutrition and medications. Repeat loading doses are not recommended due to neurotoxicity associated with prolonged plasma levels of phenylacetate. Antiemetics may be administered during infusion to aid control of infusion-associated nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Neonates, Infants, and Children &le;20 kg:  IV:  2.5 mL/kg (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg) coadministered with arginine; consider conjunctive use of hemodialysis in patients with severe hyperammonemia or refractory to sodium phenylacetate/sodium benzoate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;20 kg and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062200\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221924\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the drug metabolites and ammonia are excreted by the kidneys. Use with caution; monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221925\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221905\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [concentrate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ammonul: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221891\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221908\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Must be diluted prior to administration. Infuse via central line ONLY (administration via peripheral line may cause burning). If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary). Infuse loading dose over 90 to 120 minutes; maintenance dose is administered over 24 hours. May be an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation (may cause necrosis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221907\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hyperammonemia:</b> Adjunct to treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle enzyme deficiencies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221897\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Infection: Infection (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (4%; more common in neonates), bradycardia, cardiac failure, cardiogenic shock, cardiomyopathy, chest pain, edema, flushing, hepatic artery stenosis, hypertension, low cardiac output, myocardial rupture (atria), pericardial effusion, septic shock, subdural hematoma, thrombosis, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Decreased mental acuity (6%), seizure (6%), cerebral edema (5%), agitation (3%), coma (3%), absent reflexes, acute psychosis, aggressive behavior, ataxia, brain disease, cerebral atrophy, cerebral hemorrhage, cerebral herniation, cerebral infarction, clonus, confusion, hallucination, impaired consciousness, increased intracranial pressure, paralysis (nerve)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, maculopapular rash, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (7%), hypokalemia (7%), hyperammonemia (5%), metabolic acidosis (4%), acidosis (3%), hypocalcemia (3%), alkalosis, dehydration, fluid retention, hyperkalemia, hypernatremia, hypervolemia, respiratory acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (9%; more common in infants), diarrhea (3%; more common in infants), nausea (3%; more common in infants), abdominal distention, cholestasis, gastrointestinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3%), anuria, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (4%), disseminated intravascular coagulation (DIC; 3%), altered serum glucose, blood coagulation disorder, hemangioma, hemorrhage, increased serum pH, pancytopenia, pulmonary hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic failure, hepatotoxicity, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (3%; includes extravasation, hemorrhage at injection site, injection site blister formation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tetany, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blindness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory distress (3%), acute respiratory distress, aspiration pneumonia, dyspnea, hypercapnia, hyperventilation, Kussmaul&rsquo;s respiration, pneumothorax, pulmonary edema, respiratory alkalosis, respiratory insufficiency, tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (5%), multi-organ failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221895\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute hyperammonemia: Uncontrolled hyperammonemia can result in brain death. Immediate use of all additional therapies to decrease ammonia levels is essential including hemodialysis, caloric supplementation, and dietary protein restriction. Nonprotein calories should be supplied primarily as glucose (8 to 10 mg/kg/minute) with the addition of IV fat emulsion; attempts should be made to maintain a caloric intake of &gt;80 cal/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Infuse via central line ONLY; peripheral administration may cause burning. May be an irritant with vesicant-like properties; avoid extravasation. If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Use with caution, if at all, in patients at risk for fluid overload (eg, heart failure, severe renal impairment) or sodium retention edema; contains a significant amount of sodium. Discontinue use if patient experiences clinically significant fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Nausea and vomiting may occur; premedication with antiemetics may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: May occur; monitor plasma potassium and initiate appropriate treatment as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic acidosis/hyperventilation: Use may cause hyperventilation and metabolic acidosis; phenylacetate and benzoate are structurally similar to salicylate, therefore, adverse effects typically associated with salicylate overdose may occur with sodium phenylacetate/sodium benzoate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Phenylacetate may result in neurotoxicity (fatigue, lightheadedness, somnolence); symptoms were observed upon initiation of treatment and were reversible with discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; metabolism of sodium phenylacetate/sodium benzoate may be impaired.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; excretion of drug metabolites (phenylacetylglutamine and hippurate) and ammonia may be reduced since primarily excreted by the kidneys; use may also predispose to fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Hyperammonemic coma, regardless of the cause, should be treated aggressively until a specific diagnosis is made. Hemodialysis should be initiated immediately in all neonates and may be repeated until plasma ammonia level is stable at normal or near normal levels; a blood flow rate of 150 mL/minute/m<sup>2</sup> should be targeted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium benzoate: Contains sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Initiate therapy as soon as hyperammonemia is diagnosed. Must be diluted prior to administration. Administer through a central line; peripheral administration may result in burning. Repeat loading doses should not be administered (may result in prolonged phenylacetate plasma levels). Arginine supplementation is an essential part of therapy for patients with carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Patients should be managed by medical personnel experienced in the treatment of metabolic disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300065\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223020\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10084&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221900\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221914\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44943336\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sodium phenylacetate/sodium benzoate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sodium phenylacetate/sodium benzoate to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221915\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Contains 30.5 mg of sodium per mL of undiluted product. Caloric supplementation and dietary protein restriction should be part of treatment. Caloric intake of &gt;80 cal/kg/day should be attempted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221903\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Neurologic status, Glasgow Coma Scale, tachypnea, CT or MRI scan or fundoscopic evidence of cerebral edema, and/or of gray matter and white matter damage; plasma ammonia, plasma glutamine, plasma amino acids; blood chemistry, blood glucose, AST, ALT, blood pH and pCO<sub>2</sub>, clinical response, serum electrolytes (potassium, chloride, or bicarbonate), infusion site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221906\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Long-term target levels (may not be appropriate for every patient): </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Plasma ammonia: &lt;40 micromole/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Plasma glutamine: &lt;1,000 micromole/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221894\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium phenylacetate and sodium benzoate provide alternate pathways for the removal of ammonia through the formation of their metabolites. One mole of sodium phenylacetate removes two moles of nitrogen; one mole of sodium benzoate removes one mole of nitrogen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and renal; sodium phenylacetate conjugates with glutamine, forming the active metabolite, phenylacetylglutamine (PAG); sodium benzoate combines with glycine to form the active metabolite hippuric acid (HIP) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323874\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ammonul Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-10% (50 mL): $54,792.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sod Benz-Sod Phenylacet Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-10% (50 mL): $43,800.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ammonul (sodium phenylacetate and sodium benzoate) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):46-54.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):56-60.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brusilow SW, Danney M, Waber LJ, et al, &ldquo;Treatment of Episodic Hyperammonemia in Children With Inborn Errors of Urea Synthesis,&rdquo; <i>N Engl J Med</i>, 1984, 310(25):1630-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-drug-information/abstract-text/6427608/pubmed\" target=\"_blank\" id=\"6427608\">6427608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Consensus Statement From a Conference for the Management of Patients With Urea Cycle Disorders. Urea Cycle Disorders Conference Group,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-drug-information/abstract-text/11148503/pubmed\" target=\"_blank\" id=\"11148503\">11148503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10084 Version 76.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221922\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221934\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221923\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F221929\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062200\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F221924\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F221925\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221905\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F221891\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F221908\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F221907\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221897\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221895\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300065\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223020\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221900\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F221914\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F44943336\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F221915\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F221903\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F221906\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221894\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F221910\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323874\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10084|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-patient-drug-information\" class=\"drug drug_patient\">Sodium phenylacetate and sodium benzoate: Patient drug information</a></li><li><a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium phenylacetate and sodium benzoate: Pediatric drug information</a></li></ul></div></div>","javascript":null}